Tarsus Pharmaceuticals, Inc.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $451.4M
- Net income
- -$66.4M
- Total assets
- $562.2M
- Market cap
- $2.6B
- Operating margin
- -15.7%
- Net margin
- -14.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $451.4M
- Operating expenses
- $522.3M
- Operating income
- -$71.0M
- Income tax
- $2.1M
- Net income
- -$66.4M
- EPS (basic)
- $-1.59
- EPS (diluted)
- $-1.59
Balance sheet
- Total assets
- $562.2M
- Current assets
- $522.8M
- Total liabilities
- $218.7M
- Current liabilities
- $135.7M
- Shareholders’ equity
- $343.4M
Cash flow
- Operating cash flow
- -$12.5M
- Investing cash flow
- -$42.1M
- Financing cash flow
- $143.4M
- Net cash flow
- $88.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.6B
- EPS (diluted)
- $-1.59
- Shares outstanding
- 42.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 16, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $66.4M in FY2025.
- Revenue grew 691% from FY2021 to FY2025.
- Trading 28% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Tarsus Pharmaceuticals, Inc..
Write a review
News about Tarsus Pharmaceuticals, Inc.
News & sentiment via Polygon.io
